Skip to search formSkip to main contentSkip to account menu

linaclotide 0.29 MG Oral Capsule [Linzess]

Known as: Linzess 0.29 MG Oral Capsule, Linzess 290 MCG Oral Capsule, linaclotide 290 ug ORAL CAPSULE, GELATIN COATED [Linzess] 
National Institutes of Health

Related topics

Related topics

8 relations
Calcium ChlorideGelatinLeucineOral Capsule

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
[Pharmacological and clinical profile of linaclotide (Linzess®), a novel therapeutic agent for irritable bowel syndrome with constipation and chronic constipation].
  • Y. KetoM. Kosako
  • Nihon yakurigaku zasshi. Folia pharmacologica…
  • 2019
  • Corpus ID: 182950214
Linaclotide (Linzess® tablets 0.25 mg) is a guanylate cyclase-C (GC-C) agonist with high selectivity and binding affinity to GC-C… 
2017
2017
Linaclotide in constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: a profile of its use in the USA
Linaclotide (Linzess®) is a synthetic guanylate cyclase C agonist that acts locally in the gastrointestinal tract to increase… 
Review
2016
Review
2016
Guanylyl cyclase C signaling axis and colon cancer prevention
Colorectal cancer (CRC) is a major cause of cancer-related mortality and morbidity worldwide. While improved treatments have… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)